Agomab registers Phase 2b trial of ontunisertib in fibrostenosing Crohn's disease
Agomab Spain listed a 320-patient Phase 2b study testing three doses of ontunisertib against placebo in Crohn's patients with bowel strictures.
Agomab Spain S.L.U. registered a new dose-ranging trial for its oral drug ontunisertib in patients with fibrostenosing Crohn's disease.
- Ontunisertib (AGMB-129), Phase 2b, fibrostenosing Crohn's disease: The study is recruiting, with an estimated start of October 30, 2026 and primary completion estimated December 31, 20281. It plans to enroll 320 participants in a randomized, parallel-design trial testing Ontunisertib against placebo1, with eligible participants randomized 1:1:1:1 to receive high dose, medium dose, low dose ontunisertib or placebo for 52 weeks1. The primary outcome is the proportion of participants achieving endoscopic passability of the ileal index stricture, measured at week 241.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.